BioStock: Annexin Pharmaceuticals on the new indication cancer

In December, Annexin Pharmaceuticals revealed their plans to enter the cancer field with their candidate ANXV. In his visit to BioStock's studio, CEO Anders Haegerstrand sheds more light on the potential of the candidate in this new arena and whether the conditions for out-licensing have altered.

Watch the interview (in Swedish) with Annexin Pharmaceuticals' CEO Anders Haegerstrand here:

https://www.biostock.se/2023/03/annexin-pharmaceuticals-om-nya-indikationen-cancer/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/